Amylyx Phase III success for avexitide sets up FDA filing

Overview

Updated Oct 12

Post-bariatric hypoglycemia has no FDA-approved treatment. In August, Amylyx Pharmaceuticals reported that its Phase III LUCIDITY trial showed avexitide cut dangerous hypoglycemic events by 55% versus placebo (p=0.000003).

Avexitide is a first-in-class GLP-1 receptor antagonist — the opposite mechanism of blockbuster diabetes and obesity drugs like Ozempic and Wegovy, which activate GLP-1 receptors. After bariatric surgery, excess GLP-1 drives too much insulin release and blood sugar crashes; avexitide blocks that signal. Full results are set for presentation at ObesityWeek 2026 in November, and the company plans to file for FDA approval by year-end.

Why it matters

Avexitide could become the first approved treatment for a dangerous complication of bariatric surgery.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

55%

Reduction in hypoglycemic events

Composite rate of Level 2 and Level 3 hypoglycemic events vs placebo in LUCIDITY (p=0.000003).

160,000

Estimated U.S. PBH patients

Prevalence estimate for post-bariatric hypoglycemia in the U.S.; not confirmed in cited sources.

LUCIDITY trial participants

Randomized 3:2 to receive 90 mg avexitide subcutaneously once daily or placebo.

Avexitide trials with positive PBH results

LUCIDITY is the sixth clinical trial of avexitide in PBH with statistically significant results.

Voices

Curated perspectives — historical figures and your fellow readers.

People Involved

Camille L. Bedrosian

Chief Medical Officer, Amylyx Pharmaceuticals

Leading avexitide clinical development

Justin Klee

Co-CEO, Amylyx Pharmaceuticals

Overseeing NDA filing and commercialization strategy

Joshua Cohen

Co-CEO, Amylyx Pharmaceuticals

Overseeing NDA filing and commercialization strategy

Organizations Involved

Amylyx Pharmaceuticals

Biopharmaceutical company

Advancing avexitide toward FDA filing

Cambridge, Massachusetts-based biopharmaceutical company developing avexitide, a first-in-class GLP-1 receptor antagonist, for post-bariatric hypoglycemia.

U.S. Food and Drug Administration

Federal regulator

Will review the avexitide New Drug Application

U.S. agency that must approve avexitide before it can be marketed; granted it Breakthrough Therapy and Orphan Drug designations.

MBX Biosciences

Biopharmaceutical company

Advancing imapextide, a competing GLP-1 antagonist, in Phase IIa

Developing imapextide (MBX-1416), a long-acting GLP-1 receptor antagonist and the closest mechanistic competitor to avexitide.

Vogenx

Biopharmaceutical company

Advancing mizagliflozin toward Phase IIb

Developing mizagliflozin, an SGLT1 inhibitor targeting intestinal glucose absorption, for post-bariatric hypoglycemia.

Timeline

May 2026 October 2026

4 events Latest: October 3rd, 2026 · 1 month ago

Tap a bar to jump to that date

October 2026
NDA filing strategy detailed
Latest Regulatory Strategy

Amylyx confirms NDA submission planned before year-end, prepares for potential 2027 launch; label scope (RYGB vs broader surgery) under consideration.
October 3rd, 2026
Phase 3 LUCIDITY data scheduled for ObesityWeek 2026
Conference Presentation

Amylyx will present topline LUCIDITY results in a late-breaking oral presentation at ObesityWeek 2026, November 14-17 in Washington, D.C. A second presentation covers a machine-learning approach to identifying PBH in real-world claims data.
October 2026
August 2026
Phase III LUCIDITY meets primary endpoint
Clinical Trial Results

Amylyx reports 55% reduction in Level 2 and 3 hypoglycemic events vs placebo (p=0.000003); all secondary endpoints met; drug well-tolerated.
August 18th, 2026
May 2026
Expanded access program launches
Program Launch

Amylyx opens an expanded access program for avexitide, initially for eligible adults who completed LUCIDITY or a prior avexitide trial.
May 2026

Scenarios

FDA approves avexitide for post-bariatric hypoglycemia

Likely Resolves by End of 2027

Discussed by: Amylyx management statements

Amylyx plans to submit the NDA by year-end 2026. With Breakthrough Therapy Designation, the FDA is likely to grant priority review, compressing the standard 10-month review to about 6 months. That would put an approval decision in mid-2027, with Amylyx targeting a commercial launch later that year.

FDA requires additional data, delaying avexitide approval

Possible Resolves by Q2 2028

Discussed by: Defense World report; uncertainty over eventual indication

The eventual FDA indication remains uncertain — the label could specify PBH following Roux-en-Y gastric bypass or more broadly cover bariatric surgery. If the FDA decides the evidence base is insufficient or requests additional safety or efficacy data, it could issue a Complete Response Letter. Amylyx has said it could run an additional trial to support broader surgery-type coverage if needed.

Avexitide label covers all bariatric surgery types, not just RYGB

Possible Resolves by Q2 2028

Discussed by: Amylyx executives, noted in Defense World report

The approved label could specify PBH following Roux-en-Y gastric bypass only, or more broadly cover PBH associated with bariatric surgery. Amylyx's Phase IIb study included patients who had undergone a variety of surgeries and showed similar results across types. A broader label would expand the U.S. addressable market from about 120,000 to roughly 160,000 patients.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

2017–present

The GLP-1 drug boom (2017–present)

Semaglutide — sold as Ozempic for diabetes and Wegovy for obesity — became among the best-selling drug classes in history, turning GLP-1 receptor activation into a massive pharmaceutical franchise.

Then

GLP-1 agonists reshaped diabetes and obesity treatment and generated tens of billions in annual sales worldwide.

Now

The class validated GLP-1 signaling as a major therapeutic target and fueled research in both directions of the pathway — activation and blockade.

Why this matters now

Avexitide targets the same receptor with the opposite action: blocking GLP-1 signaling instead of activating it. The GLP-1 drug boom shows how important this pathway is, and avexitide targets the excess GLP-1 signaling that causes post-bariatric hypoglycemia.

1983

The Orphan Drug Act (1983)

Congress passed the Orphan Drug Act, creating financial incentives — including 7 years of market exclusivity — for developing drugs that treat rare diseases affecting fewer than 200,000 U.S. patients.

Then

The law spurred a wave of rare-disease drug development across the pharmaceutical industry.

Now

Hundreds of orphan-designated drugs gained approval, bringing treatments to conditions that previously had none.

Why this matters now

PBH affects roughly 160,000 people in the U.S. — under the 200,000-patient threshold. Avexitide holds Orphan Drug Designation, which would grant Amylyx 7 years of market exclusivity if approved.